全文获取类型
收费全文 | 4871篇 |
免费 | 742篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 87篇 |
儿科学 | 27篇 |
妇产科学 | 435篇 |
基础医学 | 991篇 |
口腔科学 | 86篇 |
临床医学 | 233篇 |
内科学 | 191篇 |
皮肤病学 | 191篇 |
神经病学 | 3篇 |
特种医学 | 18篇 |
外科学 | 198篇 |
综合类 | 583篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 952篇 |
眼科学 | 2篇 |
药学 | 158篇 |
3篇 | |
中国医学 | 44篇 |
肿瘤学 | 1448篇 |
出版年
2024年 | 10篇 |
2023年 | 94篇 |
2022年 | 150篇 |
2021年 | 197篇 |
2020年 | 250篇 |
2019年 | 243篇 |
2018年 | 267篇 |
2017年 | 253篇 |
2016年 | 282篇 |
2015年 | 272篇 |
2014年 | 408篇 |
2013年 | 395篇 |
2012年 | 303篇 |
2011年 | 414篇 |
2010年 | 301篇 |
2009年 | 304篇 |
2008年 | 217篇 |
2007年 | 221篇 |
2006年 | 219篇 |
2005年 | 139篇 |
2004年 | 112篇 |
2003年 | 96篇 |
2002年 | 75篇 |
2001年 | 71篇 |
2000年 | 52篇 |
1999年 | 33篇 |
1998年 | 32篇 |
1997年 | 36篇 |
1996年 | 35篇 |
1995年 | 31篇 |
1994年 | 30篇 |
1993年 | 17篇 |
1992年 | 22篇 |
1991年 | 17篇 |
1990年 | 17篇 |
1989年 | 17篇 |
1988年 | 6篇 |
1987年 | 6篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1981年 | 1篇 |
1979年 | 1篇 |
排序方式: 共有5652条查询结果,搜索用时 31 毫秒
1.
《Vaccine》2016,34(39):4724-4731
Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide. HPVs are oncogenic small double-stranded DNA viruses that are the primary causal agent of cervical cancer and other types of cancers, including in the anus, oropharynx, vagina, vulva, and penis. Prophylactic vaccination against HPV is an attractive strategy for preventing cervical cancer and some other types of cancers. However, there are few safe and effective vaccines against HPV infections. Current first-generation commercial HPV vaccines are expensive to produce and deliver.The goal of this study was to develop an alternate potent HPV recombinant L1-based vaccines by producing HPV virus-like particles into a vaccine that is currently used worldwide. Live attenuated measles virus (MV) vaccines have a well-established safety and efficacy record, and recombinant MV (rMV) produced by reverse genetics may be useful for generating candidate HPV vaccines to meet the needs of the developing world.We studied in non-human primate rMV-vectored HPV vaccine in parallel with a classical alum adjuvant recombinant HPV16L1 and 18L1 protein vaccine produced in Pichia pastoris. A combined prime-boost approach using both vaccines was evaluated, as well as immune interference due to pre-existing immunity against the MV.The humoral immune response induced by the MV, Pichia-expressed vaccine, and their combination as priming and boosting approaches was found to elicit HPV16L1 and 18L1 specific total IgG and neutralizing antibody titres. Pre-existing antibodies against measles did not prevent the immune response against HPV16L1 and 18L1. 相似文献
2.
3.
4.
The availability of human papillomavirus (HPV) vaccines and screening tests has raised the possibility of globally eliminating cervical cancer, which is caused by HPV. Cervical cancer is a very common malignancy worldwide, especially among deprived women. High vaccination coverage is key to the containment and eventual elimination of the infection. Public HPV vaccination programmes in Italy and Denmark were swiftly established and are among the most successful worldwide. Still, in both countries, it has been challenging to achieve and maintain the recommended coverage of > 80% in girls. In a well‐studied Italian region, vaccination coverage in girls at age 15 years (World Health Organization''s gold standard) reached 76% in 2015 but decreased to 69% in 2018, likely due to work overload in public immunization centres. In Denmark, doubts about safety and efficacy of the HPV vaccine generated a decline in coverage among girls age 12–17, from 80% in 2013 down to 37% in 2015, when remedial actions made it rise again. Insights from these two countries are shared to illustrate the importance of monitoring coverage in a digital vaccine registry and promptly reacting to misinformation about vaccination.
Abbreviations
- CC
- cervical cancer
- FVG
- Friuli Venezia Giulia
- HICs
- high‐income countries
- HPV
- human papillomavirus
- LMICs
- middle‐income countries
- WHO
- World Health Organization
5.
While two prophylactic HPV vaccines have been proven notably efficacious in clinical trials, the effectiveness of these vaccines at the population level remains to be evaluated. To lay the foundation for understanding the strengths and limitations of different endpoints for future effectiveness research, we present a comprehensive review of HPV-related clinical outcomes, including: (i) HPV type-specific positivity and persistence, (ii) Pap diagnoses (ASC-US, LSIL, and HSIL), (iii) histologic cervical cancer precursor lesions (i.e., CIN1, CIN2, and CIN3), (iv) invasive cervical cancer (ICC), (v) anogenital warts, (vi) recurrent respiratory papillomatosis (RRP), and (vii) other HPV-associated cancers (vulvar, vaginal, anal, penile, and oropharyngeal). While research on the vaccines’ effects on these HPV clinical outcomes in the general population is presently limited, numerous large trials will soon be completed, making a priori discussion of these potential outcomes especially urgent. Furthermore, population level systems to track HPV-associated clinical outcomes may need to be developed for HPV vaccine effectiveness evaluation. 相似文献
7.
8.
Kathleen A. Ward Sinead A. McKernan Natalina N. Durnien Wallace W. Dinsmore 《Journal of the European Academy of Dermatology and Venereology》1995,4(2):160-165
Objective Detection of HPV DNA in oral and genital lesions of a heterosexual male. 4 months after oral and vaginal intercourse with a woman with vulvar warts. Passible modes of acquisition of oral HPV infection in the male sexual partner are discussed. Setting Genitourinary Medicine clinic. Methods Polymerase chain reaction amplification of genomic DNA from oral and genital lesions. HPV DNA typing by dot blot hybridization. Results HPV DNA types 6 and 11 were identified in a polypoid tongue lesion and in a penile wart from the male sexual partner. Conclusions The acquisition of oral HPV infection in the male sexual partner may have resulted from genital-oral HPV transfer, either by direct contact with vulvar warts or by digital self-inoculation. 相似文献
9.
A quantitative immunocytochemical study of large granular lymphocytes (LGLs) in the normal cervix and in human papillomavirus (HPV) associated disease was performed using a panel of monoclonal antibodies which included those for LGL surface markers CD56, CD16, and CD57. Only CD56-positive cells were found within the ectocervical epithelium and these cells increased in number in cervical intraepithelial neoplasia (CIN) in comparison with normal cervix. Examination of serial sections and double labelling suggests that these cells are CD3+, CD8+, CD56+, CD16+. The observed increase in number of this subset was not associated specifically with HPV infection but was related to CIN. Lymphocytes expressing all three LGL markers were found in the stroma and CD16(+)-positive cells clustered around endocervical glands with occasional cells extending into the endocervical epithelium. These results indicate that a small subset of LGLs which express T-cell markers is increased in number in CIN. Cells expressing classical NK markers are restricted to the stroma and are not found within the ectocervical epithelium. 相似文献
10.
30例新鲜胃癌标本,采用多聚酶链反应技术检测人类乳头瘤病毒16、18感染、并采用多聚酶链反应-单链构象多态性技术对p53基因突变进行检测。结果:HPV15阳性率为40.0%,未发现HPV18感染:P53基因突变率为50.0%,HPV16感染和P53基因突变同时存在者为16.7%。 相似文献